Home

helps physicians and healthcare professionals

Erectile Dysfunction

helps physicians and healthcare professionals

Doctor123.org

helps physicians and healthcare professionals

Cardiac Transplantation Complications, Emergency Medicine


Basics


Description


  • Cardiac transplant recipients are a unique population with increased risk for cardiac ischemia, heart failure, as well as general risks as an immunocompromised host.
  • 1,900-2,300 cardiac transplants per yr in US
  • 1-yr survival 85-90%; 5-yr survival ~75%
  • Typical immunosuppressive therapy to control rejection is a "triple-drug"Ł regimen often including steroids.
  • Frequent biopsies are used initially to evaluate rejection; echocardiography often used in children.
  • Complications occur most commonly in the 1st 6 wk after cardiac transplantation

  • The proportion of elderly patients on the transplant list, and receiving transplants are increasing.
  • Due to changes in immune system with age, elderly transplant recipients are at increased risk of life-threatening infections, and acute rejection.

  • Pregnancy after cardiac transplant is becoming more common. Between 1988 and 2010, 63 women received either heart or heart-lung transplants. They have reported 108 pregnancies, all progressing to live births.
  • Most common complications include hypertension, pre-eclampsia, and rejection.
  • Physiologic changes that occur with pregnancy do not relate to increased rate of heart failure in transplant patients.
  • Special attention should be paid to these patients regarding rejection and infection given their immunosuppression.

Etiology


  • Rejection
    • Hyperacute rejection
      • Occurs within minutes of transplantation
      • Rare, due to ABO or other graft/host major incompatibility
      • Aggressive and immediately fatal to graft
    • Acute rejection
      • Lymphocyte infiltration and myocyte destruction
      • Most common in 1st 6 wk
      • May occur at any time
      • 75% prevalence
    • Chronic rejection
      • Fibrosis and graft vascular disease
      • Long-term complication
      • Incompletely understood etiology
      • No effective therapy
  • Cardiac allograft vasculopathy
    • Analogous to accelerated coronary artery disease in native hearts
    • Limits long-term survival, leading cause of mortality after 1 yr
  • Immune-mediated atherosclerosis
    • Form of chronic rejection
  • Infections
    • 1st mo
      • Bacterial infections are the most common cause of mortality during this high-risk time period
      • Pneumonia (Pseudomonas, Legionella, other gram-negative organisms)
      • Mediastinitis
      • Wound infection
      • UTI
    • 1st yr
      • Opportunistic and conventional infections
      • Cytomegalovirus (CMV)
      • Herpes simplex virus (HSV)
      • Legionella
      • Fungal infections
      • Pneumocystis carinii
  • Medication toxicity
    • Cyclosporine, Neoral (2nd-generation cyclosporine), tacrolimus:
      • Nephrotoxicity (30% incidence)
      • Hepatotoxicity
      • Neurotoxicity
      • Hyperlipidemia, diabetogenic
    • Azathioprine, mycophenolate mofetil:
      • Bone marrow suppression
      • Leukopenia
    • Sirolimus:
      • Hyperlipidemia
      • Wound healing
    • Steroids
      • Osteoporosis
      • Cushing disease
  • Neoplasms
    • Secondary to immunosuppression
    • 10-100 times more common vs. general population
    • Skin and lip cancer
    • Lymphomas
    • Kaposis sarcoma
    • Solid organ neoplasms

  • If the patient is not on steroids, bacteremia risk is similar to that in the general population.
  • High incidence of pneumonia
  • Patients on steroids may not show meningeal signs

Diagnosis


Signs and Symptoms


  • Acute rejection
    • Nonspecific symptoms predominate because the heart is usually denervated
    • Fatigue
    • Dyspnea
    • Low-grade fever
    • Nausea
    • Vomiting
    • May be difficult to differentiate between infection and acute rejection
  • Heart failure
    • Tachypnea
    • Rales
    • Hypoxia
    • S3
    • Murmur
    • Edema
  • Allograft vasculopathy
    • As early as 3 months after transplantation (20-50% incidence by 5 yr)
    • Denervated hearts do not present with typical angina.
    • Insidious onset
      • Fatigue
      • Cough
      • Dyspnea
    • Acute onset
      • Heart failure
      • Sudden death
      • Infarction
  • Infection (Opportunistic and conventional)
    • Fever
    • Skin lesions (zoster)
    • CMV
      • Mild (flu-like illness)
      • Fever
      • Nausea
      • Malaise
      • Pneumonitis (13-50% mortality)
      • Hepatitis
      • Gastroenteritis
      • Profound leukopenia

  • Higher risk for post-transplant lymphoproliferative disease with Epstein-Barr virus seroconversion
  • Like adults, at risk for allograft vasculopathy and its associated cardiac ischemia

Essential Workup


  • Assess for signs of rejection, cardiac dysfunction, and infarction:
    • ECG
    • Cardiac enzymes
    • Chest radiograph
    • Echocardiography
  • Possible rejection requires biopsy, consult transplant team.

Normal fever workup + chest radiograph and ECG; if on steroids, perform LP á

Diagnosis Tests & Interpretation


Lab
  • Electrolytes:
    • Cyclosporine effects:
      • Increased blood urea nitrogen, creatinine
      • Hyperkalemia
      • Metabolic acidosis
      • Hyponatremia
  • CBC:
    • Relative eosinophilia may indicate rejection over infection
  • Blood and urine culture if febrile
  • Lumbar puncture if seizures, altered mental status, or severe headache
  • BNP (expect baseline elevation)
  • CMV titers
  • Urine antigen test
  • Cyclosporine trough level

Imaging
  • ECG
    • Tachycardia
    • 20% decrease in total voltage (nonsensitive)
    • Note that normal rhythm for denervated heart is sinus 90-110 bpm
    • Depending on transplant surgical technique, may see 2 P-waves (native and donor heart):
    • Native P-waves do not correspond to quasi-random signal
  • Chest radiograph
    • Cardiomegaly
    • Pulmonary edema
    • Pleural effusions
    • Compare with previous (healthy donor heart may appear large in small recipient)
  • Echocardiography
    • Decreased mitral deceleration time
    • Initial diastolic dysfunction
    • Biventricular enlargement
    • Mitral/tricuspid regurgitation

Differential Diagnosis


  • Rejection
  • Infection
  • Ischemia
  • CMV
  • Viral illness
  • Malignancy
  • Cyclosporine toxicity

Treatment


Pre-Hospital


Adenosine should not be given to patients who have had a heart transplant as the effects may be prolonged and unpredictable. á

Initial Stabilization/Therapy


  • IV access
  • Oxygen
  • Monitor
  • Intubation
  • Defibrillation/pacing
  • Vasopressors as required
  • Arrhythmias
    • Advanced cardiac life support
    • Bradycardia does not respond to atropine; use isoproterenol

Ed Treatment/Procedures


  • Hemodynamically significant rejection
    • Methylprednisolone
    • May also require OKT3 or other anti-T-cell antibody therapy
  • Infarct/vasculopathy
    • Aspirin
    • Heparin
    • Possible angioplasty
    • Likely need retransplantation
  • CMV
    • Empiric IV ganciclovir
  • HSV
    • Oral or IV acyclovir
  • Gastroenteritis
    • Search for CMV infection with culture, serology
  • Fever without a source
    • Consult infectious disease or transplantation team
  • Headache
    • Threshold for CT scan and lumbar puncture should be low (meningitis, abscess)
  • Serious illness/trauma/operation
    • Steroid burst
    • Limit NSAID use because risk for renal insufficiency from cyclosporine and tacrolimus.

Medication


  • Acyclovir: 5-10 mg/kg IV q8h calculate dose on IBW; genital herpes: 400 mg PO TID Ś 7-10 days; varicella: 20 mg/kg up to 800 mg PO QID for 5 days
  • Ceftriaxone: 50 mg/kg IV q12-24h
  • Cyclosporine, CellCept, tacrolimus, sirolimus, Neoral, azathioprine, mycophenolate mofetil: Per transplantation team
  • Ganciclovir: Insert IV; 5 mg/kg BID for 2-3 wk (adjust for renal function)
  • Isoproterenol: 1-4 ╬╝g/min, titrate to effect; max. 10 ╬╝g/min
  • Methylprednisolone: 1 g IV; peds: 10-20 mg/kg IV
  • OKT3, daclizumab or other antibody therapy: Per transplant team

In-Patient Considerations


Admission Criteria
  • Hemodynamically significant rejection
  • Vasculopathy/ischemia
  • New dysrhythmia
  • Poorly controlled hypertension
  • Congestive heart failure
  • Dyspnea
  • Hypoxia
  • Temperature >38 ░C in adult or child on steroids
  • Suspected CMV (unexplained fever, gastroenteritis, or interstitial pneumonitis)
  • Not tolerating oral medicines
  • Syncope

Discharge Criteria
  • Mild rejection
  • Only in consultation with transplantation team
  • Fever in nontoxic child:
    • Do not give children stress-dose steroids

Additional Reading


  • Abecassis áM, Bridges áND, Clancy áCJ, et al. Solid-organ transplantation in older adults: Current status and future research. Am J Transplant.  2012;12:2608-2622.
  • Chinnock áR, Sherwin áT, Robie áS, et al. Emergency department presentation and management of pediatric heart transplant recipients. Pediatr Emerg Care.  1995;11(5):355-360.
  • Cowan áSW, Davison áJM, Doria áC, et al. Pregnancy after cardiac transplantation. Cardiol Clin.  2012;30:441-452.
  • Massad áMG. Current trends in heart transplantation. Cardiology.  2004;101:79-92.
  • Mastrobattista áJM, Gomez-Lobo áV. Pregnancy after solid organ transplantation. Obstet Gynecol.  2008;112:919-932.

Codes


ICD9


996.83 Complications of transplanted heart á

ICD10


  • T86.20 Unspecified complication of heart transplant
  • T86.21 Heart transplant rejection
  • T86.23 Heart transplant infection
  • T86.22 Heart transplant failure
  • T86.298 Other complications of heart transplant

SNOMED


  • 233932001 Cardiac transplant disorder (disorder)
  • 233933006 Cardiac transplant rejection (disorder)
  • 429257001 Disorder of transplanted heart (disorder)
Copyright © 2016 - 2017
Doctor123.org | Disclaimer